Lipella Pharmaceuticals

Historical price data

Lipella Pharmaceuticals is a clinical-stage biotech company with a mission to transform the treatment of mucosal diseases through its proprietary, localized liposomal delivery platform. The company has achieved key milestones including multiple FDA Orphan Drug Designations, positive Phase 2a data in hemorrhagic cystitis, and active Phase 2 trials in oral lichen planus and oral graft-versus-host disease. Its strategy leverages the 505(b)(2) regulatory pathway to repurpose proven drugs with novel delivery, aiming for faster, lower-risk development of therapies for areas of high unmet need.

A proprietary liposomal drug delivery system engineered specifically for mucosal administration, designed to adhere to and penetrate mucosal tissues in the bladder, oral cavity, and GI tract for targeted, localized therapy with minimized systemic exposure.

Competition varies by indication, ranging from invasive procedures and off-label generics in hemorrhagic cystitis to more advanced clinical-stage biotechs in bladder cancer. Lipella's primary differentiator is its focus on localized mucosal delivery, a relatively underexploited modality that avoids systemic toxicity.